Press releases
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
- Karyopharm to Participate at the Jefferies Global Healthcare Conference
- Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
- Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
- Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
- Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
- Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
More ▼
Key statistics
On Thursday, Karyopharm Therapeutics Inc (25K:BRN) closed at 1.45, 0.00% below its 52-week high of 1.45, set on Aug 17, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.45 |
---|---|
High | 1.45 |
Low | 1.45 |
Bid | 1.49 |
Offer | 1.52 |
Previous close | 1.45 |
Average volume | -- |
---|---|
Shares outstanding | 117.71m |
Free float | 105.70m |
P/E (TTM) | -- |
Market cap | 114.50m USD |
EPS (TTM) | -1.28 USD |
Data delayed at least 15 minutes, as of Aug 17 2023.
More ▼